User profiles for Sonya Abraham

Sonya Abraham

Imperial College
Verified email at ic.ac.uk
Cited by 2417

Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1

SM Abraham, T Lawrence, A Kleiman… - The Journal of …, 2006 - rupress.org
Glucocorticoids (GCs), which are used in the treatment of immune-mediated inflammatory
diseases, inhibit the expression of many inflammatory mediators. They can also induce the …

Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38

M Lasa, SM Abraham, C Boucheron… - … and cellular biology, 2002 - Am Soc Microbiol
The stress-activated protein kinase p38 stabilizes a number of mRNAs encoding
inflammatory mediators, such as cyclooxygenase 2 (Cox-2). In HeLa cells the anti-inflammatory …

Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised …

S Abraham, HB Juel, P Bang… - The Lancet infectious …, 2019 - thelancet.com
Background Chlamydia is the most common sexually transmitted bacterial infection
worldwide. National screening programmes and antibiotic treatment have failed to decrease …

Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway

S Alzabin, SM Abraham, TE Taher… - Annals of the …, 2012 - ard.bmj.com
Objectives To establish if changes in Th1/Th17 cell populations previously reported in
experimental arthritis occur in patients with rheumatoid arthritis (RA) treated with anti-tumour …

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis

E Pathan, S Abraham, E Van Rossen… - Annals of the …, 2013 - ard.bmj.com
Objectives To evaluate the efficacy and safety of an oral phosphodiesterase 4 inhibitor,
apremilast, in treatment of ankylosing spondylitis (AS) by monitoring symptoms and signs in a …

[HTML][HTML] Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo …

M Al-Laith, M Jasenecova, S Abraham, A Bosworth… - Trials, 2019 - Springer
Trial design We present a study protocol for a multi-centre, randomised, double-blind,
parallel-group, placebo-controlled trial that seeks to test the feasibility, acceptability and …

The evidence for microbiome manipulation in inflammatory arthritis

H Jethwa, S Abraham - Rheumatology, 2017 - academic.oup.com
The human body consists of millions of commensal bacteria (the microbiome), with the
intestinal tract being the most prevalent site of colonization. This colonization process begins at …

Covid-19 vaccine trials: Ethnic diversity and immunogenicity

H Jethwa, R Wong, S Abraham - Vaccine, 2021 - Elsevier
In recent years it has become increasingly recognised that immunogenicity of vaccines can
vary significantly between individuals, with age, comorbidities and medication use being …

Telemedicine in rheumatology at the advent of the COVID-19 pandemic

…, DD Wu, H Jethwa, S Abraham - HSS Journal®, 2020 - journals.sagepub.com
In late 2019, a hematologist from the University of North Carolina received a phone call from
space—it was a request to evaluate an astronaut on the International Space Station who …

Quantitative power Doppler ultrasound measures of peripheral joint synovitis in poor prognosis early rheumatoid arthritis predict radiographic progression

…, M Grayer, BA Fisher, M Ho, S Abraham… - …, 2016 - academic.oup.com
Objective. To assess the value of quantitative vascular imaging by power Doppler US (PDUS)
as a tool that can be used to stratify patient risk of joint damage in early seropositive RA …